Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 1/21/26 | Areteia Therapeutics | Dexpramipexole for Asthma | Subscribers Only | Subscribers Only | Subscribers Only |
| 1/20/26 | Chiesi Farmaceutici | Tanimilast for Chronic Obstructive Pulmonary Disease (COPD) | Subscribers Only | Subscribers Only | Subscribers Only |
| 1/19/26 | Pulmocide | PC-945 for Aspergillosis | Subscribers Only | Subscribers Only | Subscribers Only |
| 1/14/26 | Compass Therapeutics (CMPX) | tovecimig for Biliary Tract Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 1/13/26 | Merck & Co., Inc. (MRK) | DS-7300 for Small Cell Lung Cancer (SCLC) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/26/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 09/08/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 09/17/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |